Study finds gaps in US cell and gene therapy workforce

Call issued for more training and recruitment incentives to sustain US leadership in CGT field

Greater incentives for training and talent recruitment in cell and gene therapy manufacturing will be needed if the US is to sustain its leadership in the rapidly growing cutting-edge sector, a study has found.

The study, commissioned by the Alliance for Regenerative Medicine association of companies and academic organisations, and conducted by data company Citeline, comes in response to the government’s new National Biotechnology and Biomanufacturing Initiative, which launched in September with the aim of boosting innovation in CGT.